Progress of traditional Chinese medicine in the mult-drug resistance reversal of breast cancer

doi:10.3760/cma.j.issn.1673-422X.2014.03.012

Abstract

Abstract: Multi-drug resistance of breast cancer remains a major obstacle for effective treatment, which involves many complicated mechanisms, including drug transport in the body, metabolism and drug targets. Recent researches find that the tradition Chinese medicine not only has good effects in improving the body resistance and general situation of patients and enhancing the effects of chemoradiotherapy, but also plays a vital roles in the mutidrug resistance reversal of breast cancer.

Key words: Drugs,chinese herbal, Breast neoplasms, Drug resistance

GUO Xiao-Fei, LU Dan. Progress of traditional Chinese medicine in the mult-drug resistance reversal of breast cancer[J]. Journal of International Oncology, 2014, 41(3): 200-202.

References

［1］ Shi RZ,Li W, Zhang XL, et al.A novel indirubin derivative PHII7 potentiates adriamycin cyotoxicity via inhibiting Pglycoprotein expression in human breast cancer MCF7/ADR cells［J］. Eur J Pharmacol， 2011, 669(13):3844. ［2］ Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in bats:roles of CYP3A4 and Pgp inhibition by quercetin［J］. Arch Pharm Res, 2011, 34(4):607613. ［3］ Ning W, Sun H, Wang FP, et al. H1,a novel derivative of tetrandrine reverse Pglycoproteinmediated multidrug resistance by inhibiting transport function and expression of Pglycoprotein［J］. Cancer Chemother Pharmacol, 2011, 67(5):10171025. ［4］ Lei Y, Tan J, Michael W, et al. An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T.Wang inhibits Pglycoprotein and multidrug resistanceassociate protein 1［J］. Food Chem, 2013, 136(4):11171121. ［5］Tran TP, Kim HG, Choi JH, et al. Reversal of Pglycoproteinmediated multidrug resistance is induced by mollugin in MCF7/adriamycin cells［J］. Phytomedicine, 2013, 20(7):622631. ［6］张晔，曲秀娟，刘云鹏，等. β榄香烯对人胃癌SGC7901/Adr细胞ERK通路的活化和GSTπ表达的影响［J］. 世界华人消化杂志， 2011, 19(13):13941397. ［7］汤涛，蒙凌华，陈凌际, 等. 鸦胆子油具有多药耐药逆转和拓扑异构酶Ⅱ抑制作用［J］. 药理学通报， 2001, 17（5）:534539. ［8］高娜，茹俊卿，张青. 中药逆转白血病多药耐药研究进展［J］. 江苏中医药, 2007, 39(3):6062. ［9］邓晓慧，宋海岩，张东军. 槲皮素对乳腺癌细胞增殖及Survivin表达的影响［J］. 中国医院药学杂志, 2013, 33(12):965967. ［10］邓晓慧，宋海岩, 孙春莉. 槲皮素对人卵巢癌SKOV3细胞增殖的影响［J］. 中国病理生理杂志, 2013, 29（1）:99102. ［11］周阿成，金黑鹰，张春霞. 槲皮素对结直肠癌作用及其机制的研究进展［J］.世界华人消化杂志, 2013， 19（9）：936939. ［12］张玉洁，曹军华，吴倩, 等. 槲皮素对人肝癌SMMC7721细胞增殖和凋亡及其凋亡通路的影响［J］. 中医药导报, 2013, 19(5):9395. ［13］ Dou J, Ying GG, Wang GW, et al. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl2 and Bax regulation［J］. Mol Med Rep, 2012, 5(6):14531456. ［14］ Shan JZ, Xuan YY, Ruan SQ, et al. Proliferationinhibiting and apoptosisinducing effects of ursolic acid and oleanolic acid on multidrug resistance cancer cells in vitro［J］. Chin J Integr Med, 2011, 17(8):607611. ［15］ Zhu LT, Zhao L, Wang H, et al. OroxylinA reversePglycoproteinmediated multidrug resistance of MCF7/ADR cells by G2/M arrest［J］. Toxicol Lett, 2013, 219(2):107115. ［16］胡保全，唐鹏，齐晓伟, 等. 槐耳清膏对乳腺癌细胞系SUM159细胞干性特征的影响［J］. 第三军医大学学报, 2013, 35(11):11071110. ［17］ Mai TT, Moon J, Song Y, et al. Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells［J］. Cancer Lett, 2012, 321(2):144153. ［18］ Zhou B, Xiao XL, Xu LL, et al. A dynamic study on reversal of multidrug resistance by ginsenoside Rh2 inadriamycinresistant human breast cancer MCF7 cells［J］. Talanta, 2012, 15 (88):345351. ［19］刘观昌，赵家坤，刘诚. 金雀异黄素对人乳腺癌细胞体外增殖作用机制的研究［J］. 中国煤炭工业医学杂志, 2011, 14（10）：15161519. ［20］ Fu JM, Zhou J, Shi J, et al. Emodin affects ERCC1 expression in breast cancer［J］. J Transl Med， 2012，10Suppl 1:S7.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[12]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.